Clinical Trial Update: Safety Study of HPP593 in Subjects During and After Limb Immobilization [Phase 1]

View source ↗

Summary

Phase 1 safety study of HPP593 in subjects during and after limb immobilization was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypodynamia
• Muscle Atrophy

Drugs mentioned

• HPP593

Snippet

Sponsor: High Point Pharmaceuticals, LLC. | Conditions: Muscle Atrophy, Hypodynamia | Phase 1 | Status: TERMINATED